MODERATE TO SEVERE PSORIASIS Psoriatic Arthropathy L40.5
Conditions
Interventions
Group 1: Execution of Screening in Psoriasis patients:
Proportion of centers using the following screening measures:
- Predictors (e.g. nail involvement)
- Screening questionnaires
- Patient interview
Sponsors
AbbVie Deutschland GmbH & Co. KG
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: - Adult patients >= 18 years - Moderate to severe plaque-psoriasis - Currently on systemic psoriasis treatment - Either suspicion of joint involvement or diagnosed PsA
Exclusion criteria
Exclusion criteria: - Patients with non-plaque psoriasis - Patients not on systemic treatment - Patients not willing or able to give written informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary objective of the study is to describe the implementation of screening tools and monitoring measures for PsA in dermatological centers. Execution of screening: Proportion of centers using the following screening measures - Predictors (e.g. nail involvement) - Screening questionnaires - Patient interviews - Physical examination - Imaging procedures For patients with diagnosed PsA: a) Proportion of sites that are informed about - characteristics of PsA b) Proportion of sites that monitor (regularly): - laboratory parameters - disease activity - functional impairment - radiographic status | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary objectives are: 1.) To identify the extent and preferences for various procedures performed by different dermatological sites related to patient care of PsA-patients and 2.) To uncover patient characteristics | — |
Countries
Germany
Contacts
Public ContactThomas Mosch
AbbVie Deutschland GmbH & Co. KG
Outcome results
None listed